DOXIL approved for KS.

  title={DOXIL approved for KS.},
  author={John S. James},
  journal={AIDS treatment news},
  volume={no 236},
DOXIL, a liposomal form of the chemotherapy drug doxorubicin which allows higher concentrations to be delivered to Kaposi's sarcoma (KS) lesions or cancer tumors, has been approved by the Food and Drug Administration (FDA). The guidelines for DOXIL are the same as doxorubicin. Both may be toxic to the heart and other toxicities can occur, including neutropenia. DOXIL is given by intravenous infusion and stays in the bloodstream much longer than doxorubicin. Sequus Pharmaceuticals, Inc., the… CONTINUE READING

Similar Papers

Loading similar papers…